Dare Bioscience (DARE) Equity Average (2016 - 2025)
Dare Bioscience (DARE) has disclosed Equity Average for 10 consecutive years, with -$4.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 931.94% year-over-year to -$4.9 million, compared with a TTM value of -$4.9 million through Sep 2025, down 931.94%, and an annual FY2024 reading of -$5.5 million, down 282.37% over the prior year.
- Equity Average was -$4.9 million for Q3 2025 at Dare Bioscience, up from -$11.1 million in the prior quarter.
- Across five years, Equity Average topped out at $35.3 million in Q4 2021 and bottomed at -$11.1 million in Q2 2025.
- Average Equity Average over 5 years is $7.4 million, with a median of $1.1 million recorded in 2021.
- The sharpest move saw Equity Average skyrocketed 3788.01% in 2021, then plummeted 931.94% in 2025.
- Year by year, Equity Average stood at $35.3 million in 2021, then tumbled by 46.98% to $18.7 million in 2022, then tumbled by 119.59% to -$3.7 million in 2023, then fell by 2.18% to -$3.7 million in 2024, then tumbled by 31.73% to -$4.9 million in 2025.
- Business Quant data shows Equity Average for DARE at -$4.9 million in Q3 2025, -$11.1 million in Q2 2025, and -$7.8 million in Q1 2025.